Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras-Reference-Cited by-同舟云学术

Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras

Published:2015-12-08 Issue:2 Volume:5 Page:169-181
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Li Pengxiang¹²,Wong Yu‐Ning³,Armstrong Katrina⁴,Haas Naomi⁵,Subedi Prasun⁶,Davis‐Cerone Margaret⁶,Doshi Jalpa A.¹²

Affiliation:

1. Division of General Internal Medicine University of Pennsylvania Philadelphia Pennsylvania

2. Leonard Davis Institute of Health Economics Philadelphia Pennsylvania

3. Fox Chase Cancer Center Philadelphia Pennsylvania

4. Massachusetts General Hospital Boston Massachusetts

5. Hospital of the University of Pennsylvania Philadelphia Pennsylvania

6. Pfizer Inc. New York New York

Funder

Pfizer

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.574

Reference26 articles.

1. American Cancer Society.Cancer facts and figures. Available athttp://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf(accessed 28 July 2014).

2. Renal-Cell Carcinoma

3. Recent Progress in the Management of Advanced Renal Cell Carcinoma

4. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Utilization of Protrieve™ to Decrease Embolization Risk During Radical Nephrectomy With Inferior Vena Cava (IVC) Thrombectomy: A Case Report;Cureus;2024-08-30

2. Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment;Patient Preference and Adherence;2024-08

3. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma– results from a nation-wide study covering 50 years in Iceland;BMC Urology;2024-05-13

4. Macrophage‐Derived Nanosponges Adsorb Cytokines and Modulate Macrophage Polarization for Renal Cell Carcinoma Immunotherapy;Advanced Healthcare Materials;2024-04-30

5. Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study;Cancer Urology;2024-02-27